Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum.
Last year was a busy one for companies developing cell therapies for cancer based on engineering T-cell receptors (TCRs), known as TCR or TCR-T cell therapies. One example from the European biotech sector was the German firm Immatics, which entered the Nasdaq stock market in July 2020. Meanwhile, hefty Series A rounds were closed by T-knife in Germany and Neogene in the Netherlands.
Over the first half of 2021, however, Europe has seen few venture rounds going to TCR-T developers — a pattern also reflected in the Asia-Pacific region. But it is in big contrast to the US, which has already had at least three venture capital rounds raised by TCR-T companies. There have also been multiple initial public offerings in the US from TCR-T developers — the latest of which was closed at around €85M ($100M) by TScan Therapeutics earlier this month.
The post Europe’s TCR Therapy Scene Gains Traction with €40M Series B appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.